Scaling diagnostic kits: from prototype to manufacturing

In the In Vitro Diagnostics (IVD) industry, validating a laboratory prototype is often mistaken for the finish line.

In reality, it is just the start of the most treacherous phase: industrialization.

Transitioning an assay from a controlled R&D environment to a mass-produced kit is not a matter of simply scaling up volume. It requires re-engineering a delicate scientific process to withstand the rigors of large-scale manufacturing—without losing an atom of clinical precision.

At Diatheva, our dual capability as both a diagnostic developer and an advanced contract manufacturer gives us a front-row seat to this transition. Whether scaling a protein-based ELISA kit or a nucleic acid-based PCR assay, moving to mass production requires shifting from experimental science to rigorous process engineering.

1. The reproducibility challenge: overcoming “reagent drift”

A primary hurdle in scaling diagnostic assays is reagent drift—the potential loss of consistency when moving from small-scale research to industrial production lines.

• Analytical precision: Batch-to-batch reproducibility is a fundamental regulatory mandate. Minimal variances in enzyme concentrations, buffer pH, or antibody binding dynamics can silently shift the test’s Limit of Detection (LoD), compromising the accuracy of clinical results.
• Process stabilization: Moving from manual protocols to high-speed automated dispensing systems requires rigorous mapping of physical variables, such as viscosity, surface tension, and thermal stability. For ELISA kits, this ensures absolute uniformity of the solid-phase coating across thousands of plates. For PCR kits, it ensures mix homogeneity and prevents cross-contamination during automated master mix filling.
• The IVDR angle: Under the modern IVDR framework, any uncontrolled deviation during scale-up can be flagged as a “significant change,” potentially triggering the need for entirely new clinical evidence. Precise, validated industrialization is quite literally a regulatory insurance policy.

2. Vertical integration and supply chain control

The long-term stability and performance of an IVD kit depend heavily on robust formulation design, material selection, and the consistent quality of its individual components.

• Raw material integrity: Operating with an integrated development partner offers a profound strategic advantage. When the organization handling the scale-up directly oversees the engineering and evaluation of recombinant proteins, monoclonal antibodies, or high-purity PCR master mixes, full traceability and compliance with strict industrial specifications are assured.
• Operational continuity: Managing critical component variables in-house significantly reduces exposure to global supply chain fluctuations, ensuring a reliable, constant supply for clinical laboratories and commercial distributors.

3. Modular scalability and volume management

Many diagnostic innovators stumble during commercialization due to a stark lack of intermediate manufacturing solutions; the void between a small pilot batch and rigid, millions-of-units mass production.

Adopting a modular scalability framework allows for flexible, mid-scale batch sizes. This agility optimizes early market entry, supports clinical validation trial quantities, and significantly reduces the financial risks associated with rigid inventory management and short product shelf-lives.

The Diatheva edge: science-led industrialization

Trying to bridge the gap between a benchtop prototype and a scaled industrial product by using separate R&D firms and third-party contract manufacturers often introduces severe friction, misaligned specifications, and costly delays.

Diatheva eliminates this friction by operating in the “agile gap”, managing the entire cycle in-house, from biological raw material qualification to the final commercial kit.

• PhD-driven optimization: Innovation delivers no impact if it cannot be reliably repeated. With 70% of our team holding a PhD, we don’t just blindly follow a transfer protocol—we optimize it. Our deep expertise in molecular biology and biochemistry allows us to refine industrial workflows, frequently reducing “Time-to-Result” by up to 20% compared to standard market protocols.
• Hybrid flexibility: We specialize in flexible, mid-volume scalability. Our validated industrial workflows comfortably support batch sizes ranging from 500 to 3,000 vials/plates, providing the perfect, de-risked manufacturing scale for innovative IVD players and targeted clinical portfolios.

By mastering the delicate transition from prototype to production, we turn the complexity of scale-up into our partners’ most powerful competitive advantage.

Key takeaway for diagnostic partners

Scale-up is not just making more of the same thing; it is making the exact same thing, differently. A successful commercial launch requires designing the manufacturing process with the same scientific rigor as the original biological assay. De-risking the transition from prototype to mass production early is the most effective way to protect your investment and secure long-term market success.